SLC16A7 and cancer: In addition, we also illustrated that CHK1, CDK1, and PLK1 were associated with SLC16A7 in MDA-MB-231 and A549 cancer cells, providing a 75% validation ratio among four selected candidates (Supplementary Fig. 32).